Outcome | Phase 3 | |||
---|---|---|---|---|
12Â months to 24Â months | Baseline to 24Â months | |||
(24Â months minus 12Â months) | (24Â months minus baseline) | |||
n | Mean, 95Â % CI | n | Mean, 95Â % CI | |
Blood Pressure Medication | ||||
Taking BP lowering medication, % | ||||
 All | 237 | 0.4 % (−2.3 to 3.2) | 250 | 0.8 % (−3.0 to 4.6) |
  --African American | 169 | 1.2 %(−1.6 to 4.0) | 177 | 1.1 % (−3.3 to 5.6) |
  --White | 66 | 0.0 % (−5.9 to 5.9) | 71 | 1.4 % (−5.9 to 8.7) |
   --Lifestyle | 117 | 2.6 % (−1.1 to 6.3) | 127 | 1.6 % (−4.2 to 7.3) |
   --Wt loss, group | 48 | 2.1 % (−5.0 to 9.1) | 51 | 2.0 % (−6.6 to 10.5) |
   --Wt loss, combination | 72 | −4.2 % (−8.8 to 0.4) | 72 | −1.4 % (−7.5 to 4.7) |
Physiologic | ||||
Systolic BP, mm Hg | ||||
 LS study only | 95 | −2.8 (−6.4 to 0.7) | 104 | −4.2 (−7.3 to 1.2) ** |
 LS and HBP study | 140 | −0.2 (−3.8 to 3.5) | 146 | −9.4 (−13.4 to −5.4) *** |
 All | 235 | −1.3 (−3.9 to 1.3) | 250 | −7.2 (−9.9 to −4.6) *** |
  Subgroup by raceb | ||||
  --African American | 167 | −2.0 (−5.3 to 1.2) | 177 | −8.4 (−11.8 to −5.1) *** |
  --White | 66 | 0.9 (−3.3 to 5.2) | 71 | −4.1 (−8.5 to 0.4) |
Subgroup by interventionc | ||||
   --Lifestyle | 116 | −1.2 (−4.9 to 2.5) | 127 | −8.8 (−12.9 to −4.8) *** |
   --Wt loss, group | 47 | 0.4 (−3.9 to 4.8) | 51 | −3.9 (−8.4 to 0.6) |
   --Wt loss, combination | 72 | −2.4 (−7.8 to 2.9) | 72 | −6.8 (−11.8 to −1.9) ** |
Diastolic BP, mm Hg | ||||
 LS study only | 95 | −3.4 (−5.4 to −1.5) *** | 104 | −5.2 (−7.1 to −3.3) *** |
 LS and HBP study | 140 | −0.9 (−2.9 to 1.0) | 146 | −7.8 (−10.1 to −5.5) *** |
 All | 235 | −1.9 (−3.4 to −0.5) | 250 | −6.7 (−8.3 to −5.1) *** |
  --African American | 167 | −2.4 (−4.2 to 0.5) ** | 177 | −7.2 (−9.2 to −5.1) *** |
  --White | 66 | −1.0 (−3.0 to 1.0) | 71 | −5.4 (−7.6 to −3.3) *** |
   --Lifestyle | 116 | −1.9 (−4.0 to 0.2) | 127 | −6.8 (−9.1 to −4.4) *** |
   --Wt loss, group | 47 | −3.1 (−5.8 to −0.4) * | 51 | −7.7 (−10.7 to −4.6) *** |
   --Wt loss, combination | 72 | −1.3 (−3.9 to 1.3) | 72 | −6.0 (−8.8 to −3.2) *** |
Weight, kg | ||||
 All | 232 | 0.1 (−0.6 to 0.8) | 247 | −1.6 (−2.5 to −0.7) *** |
  --African American | 164 | −0.1 (−1.0 to .08) | 174 | −1.8 (−2.8 to −0.8) *** |
  --White | 66 | 0.6 (−0.6 to 1.7) | 71 | −1.0 (−2.9 to 0.8) |
   --Lifestyle | 113 | −0.9 (−2.0 to 0.1) | 124 | −1.7 (−2.9 to −0.5) ** |
   --Wt loss, group | 47 | 1.2 (−0.4 to 2.8) | 51 | −2.1 (−4.3 to 0.0) * |
   --Wt loss, combination | 72 | 1.0 (−0.2 to 2.2) | 72 | −1.1 (−2.7 to 0.4) |
Weight, ≥ 5 % weight loss, % | ||||
 All | 232 | 12 % (8 to 16) | 247 | 23 % (18 to 28) |
  --African American | 164 | 12 % (7 to 17) | 174 | 24 % (18 to 31) |
  --White | 66 | 12 % (4 to 20) | 71 | 18 % (9 to 27) |
   --Lifestyle | 113 | 16 % (9 to 23) | 124 | 23 % (16 to 31) |
   --Wt loss, group | 47 | 11 % (2 to 20) | 51 | 25 % (13 to 38) |
   --Wt loss, combination | 72 | 7 % (1 to 13) | 72 | 21 % (11 to 30) |
Total cholesterol, mg/dLd | ||||
 All | 196 | 1 (−3.3 to 5.0) | 211 | −3 (−7.8 to 1.7) |
  --African American | 139 | −1 (−6.3 to 4.7) | 148 | −4 (−10.3 to 1.4) |
  --White | 55 | 4 (−0.9 to 9.8) | 61 | 1 (−7.3 to 9.2) |
   --Lifestyle | 91 | 2 (−4.0 to 8.8) | 99 | −2 (−8.1 to 4.3) |
   --Wt loss, group | 41 | −3 (−13.7 to 7.2) | 46 | −9 (−20.9 to 3.7) |
   --Wt loss, combination | 64 | 1 (−4.7 to 7.1) | 66 | −1 (−9.3 to 7.2) |
HDL cholesterol, mg/dL | ||||
 All | 196 | 0 (−0.8 to 1.3) | 211 | −1 (−2.3 to 0.3) |
  --African American | 139 | 0 (−1.2 to 1.6) | 148 | −1 (−2.6 to 0.6) |
  --White | 55 | 0 (−1.4 to 2.2) | 61 | −1 (−3.1 to 1.2) |
   --Lifestyle | 91 | 0 (−1.4 to 1.7) | 99 | −2 (−4.0 to −0.1) * |
   --Wt loss, group | 41 | 0 (−2.0 to 2.3) | 46 | 1 (−1.6 to 3.6) |
   --Wt loss, combination | 64 | 0 (−1.6 to 2.4) | 66 | −1 (−2.9 to 1.4) |